Zimmerman Kate P, Oderich Gustavo, Pochettino Alberto, Hanson Kristine T, Habermann Elizabeth B, Bower Thomas C, Gloviczki Peter, DeMartino Randall R
Mayo Medical School, Mayo Clinic, Rochester, Minn.
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
J Vasc Surg. 2016 Sep;64(3):606-615.e1. doi: 10.1016/j.jvs.2016.03.427. Epub 2016 May 13.
Population-based assessment of aortic dissection (AD) hospitalizations in the general United States population is limited. We assessed the current trends in AD admissions and in-hospital mortality for surgical and medical AD treatment.
Patients admitted for primary diagnosis of AD were identified from the National Inpatient Sample database (2003-2012). Patients were identified by International Classification of Diseases-Ninth Revision diagnosis codes and categorized by treatment type: type A open surgical repair (TASR), type B open surgical repair (TBSR), thoracic endovascular aortic repair (TEVAR), and medical management (MM). Our primary outcomes were to evaluate admission trends and in-hospital mortality of AD. Secondary outcomes included postoperative complications. We used weighted national estimates of admissions to assess trends over time using linear regression. We also identified factors associated with mortality via a hierarchical multivariable logistic regression model.
We identified 15,641 patients (60.7% male; mean age, 63.5 years) admitted with a primary diagnosis of AD between 2003 and 2012. Intervention types included TASR in 3253 (20.8%), TBSR in 3007 (19.2%), TEVAR in 1417 (9.1%), and MM in 7964 (50.9%). Overall weighted admissions for AD increased significantly, from 6980 in 2003 to 8875 in 2012 (P < .01, test of trend), with increases in admission for TASR, from 1143 in 2003 to 2130 in 2012 (P < .01, test of trend), and TEVAR from 96 in 2005 to 1130 in 2012 (P < .01, test of trend). TBSR and MM admissions were stable, with TBSR admissions at 1519 in 2003 and 1540 in 2012 (P = .9, test of trend) and MM admissions at 4319 in 2003 and 4075 in 2012 (P = .8, test of trend). During the same interval, overall in-hospital mortality rates for AD decreased from 18.1% to 13.0% (P < .01, test of trend). When stratified by intervention type, mortality rates decreased for TASR, from 20.5% to 14.8% (P < .01, test of trend), for TBSR, from 18.0% to 14.3% (P = .03, test of trend), and for MM, from 17.5% to 13.9% (P < .01, test of trend). Mortality rates for TEVAR were stable, with an average mortality of 7.9% (P = .8, test of trend) during the study period. Factors associated with increased mortality included older age, Caucasian race, nonelective admission, pre-existing peripheral vascular disease, and acute postoperative complication of myocardial infarction, stroke, or kidney failure. Admissions at a center with high surgical volume were associated with a decreased mortality for TBSR admissions only (odds ratio, 0.55; 95% confidence interval, 0.4-0.7).
Overall and surgical admission rates for AD appear to be increasing, and in-hospital mortality rates are decreasing. TEVAR mortality remains mostly unchanged, however, suggesting targets for further improvement in mortality for AD treatment. Decreased mortality for TBSR at centers with a high surgical volume may suggest a need for regionalization of AD care.
基于人群对美国普通人群主动脉夹层(AD)住院情况的评估有限。我们评估了AD住院及手术和药物治疗的院内死亡率的当前趋势。
从国家住院患者样本数据库(2003 - 2012年)中识别出因AD初次诊断入院的患者。通过国际疾病分类第九版诊断编码识别患者,并按治疗类型分类:A型开放手术修复(TASR)、B型开放手术修复(TBSR)、胸主动脉腔内修复术(TEVAR)和药物治疗(MM)。我们的主要结局是评估AD的入院趋势和院内死亡率。次要结局包括术后并发症。我们使用加权全国入院估计值,通过线性回归评估随时间的趋势。我们还通过分层多变量逻辑回归模型确定与死亡率相关的因素。
我们识别出2003年至2012年间因AD初次诊断入院的15641例患者(60.7%为男性;平均年龄63.5岁)。干预类型包括TASR 3253例(20.8%)、TBSR 3007例(19.2%)、TEVAR 1417例(9.1%)和MM 7964例(50.9%)。AD的总体加权入院人数显著增加,从2003年的6980例增至2012年的8875例(P <.01,趋势检验),TASR入院人数从2003年的1143例增至2012年的2130例(P <.01,趋势检验),TEVAR从2005年的96例增至2012年的1130例(P <.01,趋势检验)。TBSR和MM入院人数稳定,TBSR入院人数2003年为1519例,2012年为1540例(P =.9,趋势检验),MM入院人数2003年为4319例,2012年为4075例(P =.8,趋势检验)。在同一时期,AD的总体院内死亡率从18.1%降至13.0%(P <.01,趋势检验)。按干预类型分层时,TASR死亡率从20.5%降至14.8%(P <.01,趋势检验),TBSR从18.0%降至14.3%(P =.03,趋势检验),MM从17.5%降至13.9%(P <.01,趋势检验)。TEVAR死亡率稳定,研究期间平均死亡率为7.9%(P =.8,趋势检验)。与死亡率增加相关的因素包括年龄较大、白种人、非择期入院、既往存在外周血管疾病以及心肌梗死、中风或肾衰竭的急性术后并发症。仅在手术量高的中心进行的TBSR入院与死亡率降低相关(比值比,0.55;95%置信区间,0.4 - 0.7)。
AD的总体和手术入院率似乎在增加,院内死亡率在降低。然而,TEVAR死亡率基本保持不变,这提示AD治疗死亡率有进一步改善的目标。手术量高的中心TBSR死亡率降低可能表明需要对AD护理进行区域化。